華大基因(300676.SZ):控股子公司新冠核酸檢測產品獲得CE准入資質
格隆匯6月24日丨華大基因(300676.SZ)公佈,公司控股子公司深圳華大因源醫藥科技有限公司(以下簡稱華大因源)的新型冠狀病毒(以下簡稱新冠)核酸檢測試劑盒(自驅動微流控-試紙條法)於近日獲得了歐盟CE准入資質。

新冠肺炎與其他病原體引起的呼吸道感染早期症狀相似,快速、便捷的檢測和精準鑑別對新冠疫情防控具有重要作用。華大因源此次獲得CE准入資質的是基於自驅動微流控-試紙條法的新冠核酸檢測產品,方便在非專業實驗室、基層醫療衞生機構等進行快速檢測,擴大了新冠核酸檢測產品的應用場景,能夠快速、準確評估感染狀況以輔助感染排查,促進患者早期診斷與及時公共衞生干預,能較好地提高核酸檢測在各種場景下的可及性,滿足各國疫情防控需求,在全球範圍內助力新冠疫情防控工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.